Introduction：Basic information about CAS 128270-60-0|Bivalirudin trifluoroacetate salt, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Bivalirudin trifluoroacetate salt |
|---|
| CAS Number | 128270-60-0 | Molecular Weight | 2295.31 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C98H138N24O33 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | bivalirudin |
|---|
| Synonym | More Synonyms |
|---|
Bivalirudin trifluoroacetate salt BiologicalActivity
| Description | Bivalirudin Trifluoroacetate is a synthetic 20 residue peptide which reversibly inhibits thrombin.IC50 Value:Target: thrombinin vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) [1]. In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l [2]. Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications [3].in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats [4]. Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent [5].Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4 |
|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Thrombin |
|---|
| In Vivo | Bivalirudin (2 mg/kg) delays both the time for appearance of first thrombus and the time for occlusion in P2Y12+/+ arteries, although neither prevented vessel occlusion[2]. |
|---|
| References | [1]. Bates ER, et al. Bivalirudin: an anticoagulant option for percutaneous coronary intervention.Expert Rev Cardiovasc Ther. 2004 Mar;2(2):153-62. [2]. André P, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.Circulation. 2003 Nov 25;108(21):2697-703. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Molecular Formula | C98H138N24O33 |
|---|
| Molecular Weight | 2295.31 |
|---|
| PSA | 901.57000 |
|---|
| LogP | -2.24 |
|---|
| Index of Refraction | 1.675 |
|---|
| InChIKey | OIRCOABEOLEUMC-GEJPAHFPSA-N |
|---|
| SMILES | CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(N)Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)O |
|---|
| Storage condition | ?20°C |
|---|
Safety Information
Customs
Synonyms
| Bivalirudin Trifluoroacetate |
| Angiox |
| L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamy 
l-L-α-glutamyl-L-tyrosyl- |
| D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine |
| D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-g lutamyl-L-tyrosyl-L-leucine |
| L-leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl- |
| bivalirudina |
| Hirulog-1 |
| Bivalirudin |
| Hirulog |
| Angiomax |
| BG-8967 |
| Bivalirudin (Trifluoroacetate) |
